Equities

Establishment Labs Holdings Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Establishment Labs Holdings Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)73.99
  • Today's Change1.27 / 1.75%
  • Shares traded284.62k
  • 1 Year change+145.32%
  • Beta0.9385
Data delayed at least 15 minutes, as of Feb 12 2026 20:14 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.

  • Revenue in USD (TTM)190.97m
  • Net income in USD-82.98m
  • Incorporated2013
  • Employees1.02k
  • Location
    Establishment Labs Holdings IncBuilding B15 And 25 Coyol Free ZoneALAJUELA 20101Costa RicaCRI
  • Phone+506 24342400
  • Websitehttps://establishmentlabs.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Procept Biorobotics Corp299.91m-84.58m1.59bn756.00--4.19--5.31-1.54-1.545.456.810.67721.813.91396,702.40-19.10-26.94-21.74-29.8164.5554.37-28.20-83.147.20--0.1194--64.84105.2113.68---10.34--
Kestra Medical Technologies Ltd74.26m-138.79m1.63bn330.00--8.73--21.88-2.76-2.761.473.190.4034--9.40225,027.30-71.43-122.23-92.37-192.3546.40---177.06-342.51---116.720.2033--115.05---25.08--150.61--
AtriCure Inc518.31m-28.77m1.64bn1.30k--3.43--3.16-0.608-0.60810.909.590.8291.688.79398,696.20-4.60-3.84-5.24-4.2574.8774.53-5.55-7.132.85-17.960.1252--16.5515.05-46.85--14.00--
Omnicell Inc1.18bn2.05m1.70bn3.60k874.861.3820.731.430.04320.043225.7027.450.57867.195.01--0.10020.73310.13570.976742.4944.800.17321.321.22--0.1198--6.535.84-83.62-42.341.93--
AxoGen Inc214.71m-2.10m1.70bn451.00--12.94350.167.91-0.0486-0.04864.562.621.051.557.75476,073.20-1.03-11.36-1.17-13.0574.7678.42-0.9767-15.372.640.64930.2852--17.8111.9154.12---2.84--
Pulse Biosciences Inc86.00k-74.73m1.71bn75.00--18.45--19,896.88-1.14-1.140.00131.370.0009----1,146.67-74.06-83.75-80.63-94.40-224.42---86,898.84-12,644.5210.01--0.00-------26.95---27.12--
Artivion Inc422.65m-9.12m1.90bn1.60k--4.33137.124.49-0.242-0.2429.489.260.5091.725.16264,153.80-1.10-2.47-1.29-2.6664.5065.02-2.16-5.892.881.290.3324--9.757.0656.37--6.75--
Quidelortho Corp2.71bn-1.18bn1.96bn6.60k--0.9603--0.7208-17.38-17.3840.1129.990.43512.417.18411,272.70-18.910.0044-22.090.00547.1559.13-43.450.0090.98050.65370.56630.00-7.1739.07-20,216.83--48.27--
Inspire Medical Systems Inc911.98m56.67m1.98bn1.25k35.292.5028.052.171.934.9730.7527.331.061.188.57--6.610.07167.400.080685.3984.836.210.07064.56------13.6051.215.91------
LeMaitre Vascular Inc240.87m53.34m1.99bn651.0038.475.2531.308.272.282.2810.3516.710.4941.037.45369,993.8010.949.0911.699.8970.9766.2422.1416.6411.45--0.307738.3813.6313.4046.2819.6813.1115.91
Alphatec Holdings Inc728.02m-154.96m2.00bn867.00--174.84--2.75-1.05-1.054.910.23510.94971.287.90839,700.10-20.21-27.43-26.81-34.6969.2366.99-21.29-39.401.24-1.860.941--26.8140.0713.14--48.19--
UFP Technologies Inc597.95m67.12m2.03bn4.15k30.595.0323.653.408.618.6176.7152.370.92614.896.86144,223.8010.4010.1211.8711.5328.5127.0711.2310.641.368.390.26570.0026.0820.5231.2924.4610.82--
Establishment Labs Holdings Inc190.97m-82.98m2.11bn1.02k--129.13--11.06-2.84-2.846.530.56320.61450.7692.75187,596.30-26.70-31.53-33.25-39.3268.7465.46-43.45-45.092.10-1.720.9377--0.529213.14-7.76--17.33--
Heartflow Inc-100.00bn-100.00bn2.30bn699.00--8.84----------3.05----------------------------0.00--44.32--22.04------
Neogen Corp880.32m-602.74m2.34bn2.97k--1.11--2.66-2.78-2.784.059.670.23752.635.95296,005.00-16.26-7.73-16.94-8.0645.9848.10-68.47-27.912.80-0.21090.2737---3.2016.43-11,491.59--34.18--
10X Genomics Inc641.81m-76.32m2.42bn1.31k--3.09--3.78-0.6249-0.62495.196.200.65322.5610.08491,434.90-7.77-25.61-9.00-29.1968.9074.03-11.89-47.524.06--0.00---1.2819.9628.41---20.72--
Data as of Feb 12 2026. Currency figures normalised to Establishment Labs Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

60.65%Per cent of shares held by top holders
HolderShares% Held
JW Asset Management LLCas of 31 Dec 20253.06m10.57%
RTW Investments LPas of 30 Sep 20252.59m8.94%
Qatar Investment Authority (Investment Management)as of 31 Mar 20252.39m8.25%
Brown Advisory LLCas of 30 Sep 20252.17m7.48%
Nantahala Capital Management LLCas of 30 Sep 20251.97m6.81%
Findell Capital Management LLCas of 30 Sep 20251.30m4.47%
BAMCO, Inc.as of 30 Sep 20251.18m4.08%
Tyro Capital Management LLCas of 30 Sep 20251.08m3.72%
William Blair Investment Management LLCas of 30 Sep 20251.02m3.51%
Morgan Stanley & Co. LLCas of 30 Sep 2025817.24k2.82%
More ▼
Data from 30 Sep 2025 - 18 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.